Barrons.com2d agoneutral
Review & Preview: Earnings’ Last GaspNvidia and Walmart will close out a strong earnings season later this week but investors are looking for signs of inflation-weary consumers.
ニュース
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
316last 24h
1485last 7d
249🟢 bullish (7d)
151🔴 bearish (7d)
143publishers
Reuters Videos2d agoneutralVIDEO
US stocks end mixed as tech stocks slide, Treasury yields climb<body><p>STORY: Wall Street's main indexes ended mixed on Monday, with the Dow adding about a third of a percent, the S&P 500 little changed and the tech-heavy Nasdaq shedding half a percent.</p><p>Ongoing worries about the disruption of oil supplies, inflation and elevated borrowing costs weighed on stocks and pushed the 10-year Treasury yield earlier in the session to its highest level since February 2025.</p><p>Kevin Mahn is president and chief investment officer at Hennion & Walsh Asset Management.</p><p>“Investors continue to try and digest higher oil prices, which have led to higher gas prices and introduced even more inflationary pressures into the system. So each time we hear news that the impasse in the Strait of Hormuz may be coming to an end, you see the tailwind come into the market and stocks move higher. On the flip side, each time we learn that that Strait of Hormuz is going to be locked, or at least blocked for a longer period of time, investors then get concerned, bond yields shoot up and the prospects for a rate hike as opposed to a rate cut get brought back on to the table."</p><p>The Nasdaq fell for a second consecutive session as investors took a break from the AI-driven rally that started in late March.</p><p>Seagate Technology fell almost 7%, while peer Micron shed 6%. Shares of Sandisk dropped more than 5% and Western Digital lost nearly 5%. </p><p>:: Nvidia</p><p>The world's most valuable company, Nvidia, also closed lower, ahead of its scheduled quarterly earnings report later this week.</p><p>:: Archive</p><p>Elsewhere in the market, shares of Regeneron tumbled almost 10% as the drugmaker's experimental treatment for melanoma missed the main goal in a late-stage trial.</p></body>
